Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P16035
UPID:
TIMP2_HUMAN
Alternative names:
CSC-21K; Tissue inhibitor of metalloproteinases 2
Alternative UPACC:
P16035; Q16121; Q93006; Q9UDF7
Background:
Metalloproteinase inhibitor 2, also known as Tissue inhibitor of metalloproteinases 2 and CSC-21K, plays a crucial role in the regulation of extracellular matrix composition. It forms complexes with metalloproteinases, including MMP-1, MMP-2, and MMP-9, and inactivates them by binding to their catalytic zinc cofactor, thus preventing the breakdown of matrix components.
Therapeutic significance:
Understanding the role of Metalloproteinase inhibitor 2 could open doors to potential therapeutic strategies. Its ability to regulate metalloproteinases suggests its potential in treating diseases characterized by excessive extracellular matrix degradation, such as arthritis and cancer metastasis.